Ex-Genzyme chief's $10M gift kicks off MGH cancer center

Biotech pioneer Henri Termeer (photo) can now add a startup to his resume. After recently retiring from Genzyme in the wake of the big Sanofi ($SNY) buyout, Termeer is seeding the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital with a $10 million donation. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.